Back to Search
Start Over
Abstract 2658: Immunological and mutational landscape of gallbladder adenocarcinoma
- Source :
- Cancer Research. 80:2658-2658
- Publication Year :
- 2020
- Publisher :
- American Association for Cancer Research (AACR), 2020.
-
Abstract
- Introduction Gallbladder adenocarcinoma (GBC) is a relatively rare malignancy with high mortality rate due to late stage discovery. At advanced-stages, there are limited treatment options, and most patients develop resistance to chemotherapy. Adapting the recent major advances in cancer immunotherapy specifically to GBC will require a deep understanding of the immune landscape. Our aim is to characterize Immune Checkpoint markers (IC), Tumor infiltrating Lymphocytes (TILs), and Myeloid cells (MCs), and associate them with cancer genomic alterations, clinic-pathological information, and patient survival. Methods We selected formalin-fixed and paraffin-embedded tumor tissues from surgically resected primary GBC (n=97 patients) without neoadjuvant therapy to construct a tissue microarray. Tumor samples were collected from two institutions (MD Anderson Cancer Center (MDACC), USA, n=53; Sotero del Rio Hospital (SRH), Chile, n=44). We performed immunohistochemistry with the following biomarkers: IC (PD-1, PD-L1, LAG-3, TIM-3, B7-H3, B7-H4, VISTA, ICOS, OX-40, IDO1), TILs (CD3, CD4, CD8, CD45RO, CD57, GZB, FOXP-3, CD20), and MCs (CD68, CD11b, CD14). The evaluation of PD-L1, B7-H3, B7-H4, and IDO1 was performed in malignant cells and scored as percentage of positive cells. The TILs and IC were scored as cell densities (n/mm2) using digital image analysis. Tumors were classified in 4 types based on PD-L1 expression and CD8 densities (cut-off median): I (PD-L1+/CD8high), II (PD-L1-/CD8low), III (PD-L1+/CD8low), and IV (PD-L1-/CD8high). Next Generation sequencing platform T200 was used to access genomic alterations in a subset of cases (n=58). Results Expression of PD-L1, B7-H3, B7-H4, and IDO1 (cutoff ≥1%) was 4, 12, 7, and 22 % respectively. From all tumors, 49% were type IV, 47% type II, 3% type I, and 1% type III. Comparing MDACC and SRH cohort, densities of CD3, CD4, TIM3, and PD-1 were higher in tumors from SRH (p Conclusions We characterize the immunological landscape of gallbladder adenocarcinoma. Most tumors were immune ignorant or tolerant (Type II or IV). Different genomic alterations may have distinct immune patterns. Citation Format: Fernando Cintra Lopes Carapeto, Luisa Maren Solis Soto, Wai Chin Foo, Wei Lu, Eduardo A. Vinuela Fawaz, Miguel A. Villaseca, Eduardo Alberto Vega Pizarro, Juan C. Araya, Ignacio I. Wistuba, Javle Milind, Pant Shubham, Lawrence Kwong. Immunological and mutational landscape of gallbladder adenocarcinoma [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2658.
- Subjects :
- 0301 basic medicine
CD20
Oncology
Cancer Research
medicine.medical_specialty
Tissue microarray
biology
Tumor-infiltrating lymphocytes
business.industry
medicine.medical_treatment
Cancer
medicine.disease
Malignancy
Immune checkpoint
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
030220 oncology & carcinogenesis
Internal medicine
medicine
biology.protein
Immunohistochemistry
business
Neoadjuvant therapy
Subjects
Details
- ISSN :
- 15387445 and 00085472
- Volume :
- 80
- Database :
- OpenAIRE
- Journal :
- Cancer Research
- Accession number :
- edsair.doi...........4feeb99b89420d469badb0b3683ed2af
- Full Text :
- https://doi.org/10.1158/1538-7445.am2020-2658